|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0025202,
umls-concept:C0030705,
umls-concept:C0042210,
umls-concept:C0205179,
umls-concept:C0220905,
umls-concept:C0536940,
umls-concept:C0599946,
umls-concept:C0871261,
umls-concept:C1413787,
umls-concept:C1529741,
umls-concept:C1704632,
umls-concept:C1704858,
umls-concept:C1706817,
umls-concept:C2825965,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-3-17
|
|
pubmed:abstractText |
NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. We recently developed a vaccine consisting of full-length recombinant NY-ESO-1 protein formulated with ISCOMATRIX adjuvant, which generated strong humoral and T-cell-mediated immune responses and seemed to reduce the risk of disease relapse in patients with fully resected melanoma. This study examines the clinical and immunologic efficacy of the same vaccine in patients with advanced metastatic melanoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/CTAG1B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/ISCOMATRIX,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Phospholipids,
http://linkedlifedata.com/resource/pubmed/chemical/Saponins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:CebonJonathanJ,
pubmed-author:ChenWeisanW,
pubmed-author:CoeW CWC,
pubmed-author:DavisIan DID,
pubmed-author:DimopoulosNektariaN,
pubmed-author:EbertLisa MLM,
pubmed-author:HoffmanEric WEW,
pubmed-author:HopkinsWendieW,
pubmed-author:JacksonHeatherH,
pubmed-author:MaraskovskyEugeneE,
pubmed-author:McArthurGrant AGA,
pubmed-author:MiloradovicLenaL,
pubmed-author:NicholaouTheoT,
pubmed-author:PanLindaL,
pubmed-author:VenhausRalphR
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2166-73
|
|
pubmed:meshHeading |
pubmed-meshheading:19276262-Adjuvants, Immunologic,
pubmed-meshheading:19276262-Adult,
pubmed-meshheading:19276262-Aged,
pubmed-meshheading:19276262-Aged, 80 and over,
pubmed-meshheading:19276262-Antigens, Neoplasm,
pubmed-meshheading:19276262-Cancer Vaccines,
pubmed-meshheading:19276262-Cholesterol,
pubmed-meshheading:19276262-Drug Combinations,
pubmed-meshheading:19276262-Female,
pubmed-meshheading:19276262-Humans,
pubmed-meshheading:19276262-Hypersensitivity, Delayed,
pubmed-meshheading:19276262-Male,
pubmed-meshheading:19276262-Melanoma,
pubmed-meshheading:19276262-Membrane Proteins,
pubmed-meshheading:19276262-Middle Aged,
pubmed-meshheading:19276262-Phospholipids,
pubmed-meshheading:19276262-Saponins,
pubmed-meshheading:19276262-T-Lymphocytes,
pubmed-meshheading:19276262-T-Lymphocytes, Regulatory,
pubmed-meshheading:19276262-Vaccination
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, Austin Health, Peter MacCallum Cancer Centre, CSL Limited, Melbourne, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
